US20140170180A1 - Porcine parvovirus 5a, methods of use and vaccine - Google Patents

Porcine parvovirus 5a, methods of use and vaccine Download PDF

Info

Publication number
US20140170180A1
US20140170180A1 US13/796,621 US201313796621A US2014170180A1 US 20140170180 A1 US20140170180 A1 US 20140170180A1 US 201313796621 A US201313796621 A US 201313796621A US 2014170180 A1 US2014170180 A1 US 2014170180A1
Authority
US
United States
Prior art keywords
seq
ppv5a
polypeptide
infection
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/796,621
Other languages
English (en)
Inventor
Arun V. IYER
Dianna M. Murphy JORDAN
Abby Rae PATTERSON
Michael B. Roof
Eric Martin VAUGHN
Joseph Gilbert VICTORIA
Callie Ann VISEK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50931160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20140170180(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Priority to US13/796,621 priority Critical patent/US20140170180A1/en
Assigned to BOEHRINGER INGELHEIM VETMEDICA, INC. reassignment BOEHRINGER INGELHEIM VETMEDICA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JORDAN, DIANNA M. MURPHY, ROOF, MICHAEL B., IYER, ARUN V., PATTERSON, ABBY RAE, VAUGHN, ERIC MARTIN, VICTORIA, JOSEPH GILBERT, VISEK, CALLIE ANN
Priority to TW107130755A priority patent/TW201920662A/zh
Priority to TW102146453A priority patent/TWI656213B/zh
Priority to DK13814791.3T priority patent/DK2931741T3/en
Priority to SG11201504805PA priority patent/SG11201504805PA/en
Priority to UAA201506962A priority patent/UA117467C2/uk
Priority to ES13814791.3T priority patent/ES2689515T3/es
Priority to JP2015547995A priority patent/JP6072935B2/ja
Priority to EA201500643A priority patent/EA031278B1/ru
Priority to MX2015007723A priority patent/MX2015007723A/es
Priority to PCT/US2013/075059 priority patent/WO2014099669A1/en
Priority to CA2894708A priority patent/CA2894708A1/en
Priority to EP13814791.3A priority patent/EP2931741B1/en
Priority to AU2014203571A priority patent/AU2014203571B2/en
Priority to KR1020157019338A priority patent/KR102197266B1/ko
Publication of US20140170180A1 publication Critical patent/US20140170180A1/en
Priority to US14/713,700 priority patent/US9833507B2/en
Priority to CL2015001689A priority patent/CL2015001689A1/es
Priority to PH12015501378A priority patent/PH12015501378A1/en
Priority to CO15166795A priority patent/CO7461133A2/es
Assigned to Boehringer Ingelheim Animal Health USA Inc. reassignment Boehringer Ingelheim Animal Health USA Inc. MERGER AND CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: Boehringer Ingelheim Animal Health USA Inc., BOEHRINGER INGELHEIM VETMEDICA, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention is in the field of animal health and relates to novel porcine parvovirus strains, including attenuated strains for vaccination, methods of manufacture and methods of treatment using vaccines obtained from said novel parvovirus strains.
  • Parvoviruses infect a wide variety of animal species, and some of them are responsible for severe clinical diseases, but the majority of these viruses cause only mild or subclinical infections. They belong to the family Parvoviridae and form two subfamilies: Densovirinae, whose members infect insects, and Parvovirinae, whose members infect vertebrates. The latter subfamily currently includes five genera: Dependovirus, Erythrovirus, Amdovirus, Bocavirus and Parvovirus (1).
  • Parvovirus virions are non-enveloped and contain single-stranded, linear DNA genomes of approximately 5-6 kilobases (kb).
  • the genome consists of two main open reading frames (ORF) that encode the non-structural and capsid proteins.
  • ORF open reading frames
  • the newly described bocaviruses carry a third ORF, between the two major ORFs (1).
  • porcine parvovirus The classical porcine parvovirus (PPV1) strains of the genus Parvovirus are widely distributed around the world and are responsible for reproductive disorders of pigs, especially in herds where vaccination protocols are not followed correctly or vaccine efficacy is decreased due to immunosuppressive factors.
  • PPV2 porcine parvovirus 2
  • PHoV porcine parvovirus 2
  • BHoV hokoviruses
  • PPV4 shows the highest similarity to bovine parvovirus 2, but the coding capacity and genome organization are similar to those of bocaviruses, as PPV4 encodes an additional ORF3 like bocaviruses, located between ORF1 and ORF2.
  • the PPV4-encoded putative ORF3 protein is quite different from that of bocaviruses (5).
  • the present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new parvovirus strains that infect, inter alia, domestic swine. These strains are related to the novel porcine parvovirus identified in tissue samples from clinically diseased domestic swine; based on sequence homology with known porcine parvovirus species and strains, the novel virus was denominated porcine parvovirus 5A or PPV5A.
  • compositions and methods of the invention provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
  • Immunogenic compositions and vaccines of the invention comprise polypeptide sequences encoded by the nucleic acid sequence of SEQ ID NO:1, or immunogenic fragments thereof, optionally including adjuvants for inducing a more robust immunogenic response.
  • compositions of the invention comprise any one of the polypeptide sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ NO:4, or fragments thereof that are immunoreactive to antibodies specific for PPV5A.
  • Preferred polypeptides of the invention include the sequences of SEQ ID NO:2 or SEQ ID NO:4, in particular SEQ ID NO:4.
  • Preferably those polypeptides, or fragments thereof, are immunoreactive to antibodies specific for PPV5A.
  • the invention provides nucleic acid sequences that encode one or more polypeptides, antibody constructs, or antibody conjugates.
  • the gene sequences coding for the polypeptides comprise a nucleic acid sequence that is at least 95%, 90%, 85%, or even 80% homologous to and/or identical with the sequence of SEQ ID NO: 1, in particular, nucleotide sequences 2845-5547 of SEQ ID NO:1 (the capsid protein), or fragments of SEQ ID NO:1 coding for a polypeptide that is immunoreactive to antibodies specific for PPV5A.
  • nucleic acid sequences of the invention include any one of the sequences of nucleotides 1975-2844 of SEQ ID NO:1, and nucleotides 2845-5547 of SEQ ID NO:1, and fragments thereof, that encode a polypeptide that is immunoreactive to an antibody specific for PPV5A.
  • the nucleic acid sequences, or genes are those coding for a polypeptide or peptide that is immunoreactive to an antibody specific for PPV5A.
  • polypeptide of the invention as used herein includes but is not limited to a polypeptide that comprises:
  • Immunogenic compositions of the invention which comprise at least one or more PPV5A polypeptides as defined herein may further comprise a physiologically-acceptable vehicle such as a pharmaceutically or veterinary-acceptable carrier, adjuvant, or combination thereof.
  • a physiologically-acceptable vehicle such as a pharmaceutically or veterinary-acceptable carrier, adjuvant, or combination thereof.
  • any of the PPV5A polypeptides provided herewith or any immunogenic compositions comprising one or more of these PPV5A polypeptides provided herewith can be used as a medicament, preferably as a vaccine or immunogenic composition, most preferably for the prophylaxis or treatment of a subject against a PPV5A infection.
  • Particularly preferred PPV5A polypeptides include those with immunogenic epitopes that induce an immunological response that is specific for PPV5A.
  • Preferred PPVA polypeptides include those having an amino acid sequences predicted in related PPV1 to be surface antigens (Simpson et al. JMB 315, 2002) and include, but is not limited to residues 141-156, 272-278, and 329-339 of SEQ ID NO:4.
  • compositions used herein may incorporate known injectable, physiologically acceptable sterile solutions.
  • aqueous isotonic solutions e.g. saline or plasma protein solutions
  • the immunogenic and vaccine compositions of the present invention can include veterinary-acceptable carriers, diluents, isotonic agents, stabilizers, or adjuvants.
  • Methods of the invention include, but are not limited to, a method of provoking an immune response against a PPV5A infection in a subject comprising the step of administering to the subject an immunogenic composition comprising one or more PPV5A polypeptides as defined herein.
  • the immune response is provoked against more than one serotype or strain of PPV5A.
  • Compositions of the invention may be used to treat or alternatively to prevent a PPV5A infection.
  • such immune response reduces the incidence of or severity of one or more clinical signs associated with or caused by the infection with one or more PPV5A serotypes.
  • suitable subjects and subjects in need to which compositions of the invention may be administered include animals in need of either prophylactic or treatment for a viral, microbial, parasitic, protozoan, bacterial, or fungal associated infection, disease, or condition.
  • Animals in which the immune response is stimulated by use of compositions or methods of the invention include livestock, such as porcine, bovine, poultry (e.g. chickens, ducks, geese, or turkeys) caprine, and ovine, and domestic animals, such as mice, rabbits, dogs, cats, and horses.
  • Preferred animals include swine, murids, equids, lagomorphs, and bovids. Most preferably, an immune response is stimulated in swine.
  • the invention also provides a method of reducing the incidence of or severity of one or more clinical signs associated with or caused by PPV5A infection, comprising the step of administering an immunogenic composition of the invention that comprises one or more PPV5A peptides as provided herewith and preferably a carrier molecule, such that the incidence of or the severity of a clinical sign of the PPV5A infection is reduced by at least 10%, preferably at least 20%, even more preferred at least 30%, even more preferred at least 50%, even more preferred at least 70%, most preferred at least 100% relative to a subject that has not received the immunogenic composition as provided herewith.
  • Such clinical signs include viremia and immunosuppression as a result from an infection with PPV5A alone.
  • Such clinical signs may include neurological signs (depression, ataxia, lethargy), diarrhea, dyspnea, loss of body condition, swelling of joints (resulting in lameness and recumbency), decreased average daily weight gain, mortality, and polyserositis as a result of a co-infection with another organism, e.g., Mycoplasma hyorhinis.
  • the present invention also relates to a method for the prophylaxis of a PPV5A infection, wherein said PPV5A infection may be caused by PPV5A having 100% sequence identity with the nucleotide sequences of SEQ ID NOs 1, 2, 3 and/or 4, having at least 95% sequence identity with the nucleotides sequences of SEQ ID NOs 1, 2, 3 and/or 4, having at least 90% sequence identity with the nucleotides sequences of SEQ ID NOs 1, 2, 3 and/or 4, or having at least 85% sequence identity with the nucleotides sequences of SEQ ID NOs 1, 2, 3 and/or 4, comprising the step of administering an immunogenic composition of the invention that comprises one or more PPV5A peptides as provided herewith.
  • the invention also provides a method of preparing any of the immunogenic compositions provided herewith that method comprises mixing one or more PPV5A peptides as provided herewith with a carrier molecule, preferably such that the one or more PPV5A peptides and carrier molecule are covalently coupled or conjugated to one another.
  • Such conjugates may be multivalent or univalent.
  • Multivalent compositions or vaccines include an immuno-conjugation of multiple PPV5A peptides with a carrier molecule.
  • the invention provides a method of producing one or more PPV5A peptides that method comprises transforming a host cell, preferably a prokaryotic cell such as E.
  • the host cell may be a eukaryotic cell such as an animal cell, an insect cell, a protist cell, a plant cell, or a fungal cell.
  • the eukaryotic cell is a mammalian cell such as CHO, BHK or COS, or a fungal cell such as Saccharomyces cerevisiae, or an insect cell such as Sf9.
  • Baculovirus expression of the nucleic acids of the instant invention are also preferred.
  • Another aspect of the invention provides a method of producing one or more PPV5A peptides that induce an immune response against at least one genetic variants of PPV5A and more preferably two or more genetic variants of PPV5A.
  • This comprises culturing a transformed expression vector coding for and expressing one or more PPV5A peptides disclosed herein.
  • the expressed proteins are either retained by the expression organism or secreted into the culture medium. Expression is conducted under conditions sufficient to produce a PPV5A peptide capable of inducing an immune response to PPV5A.
  • the PPV5A serotypes to which the PPV5A peptides induce an immune response include but are not limited to sequences having at least 99, 98, 97, 96, 95, 94, 93, 92, 91 or 90% identity.
  • compositions of the invention may further comprise admixing the conjugate of one or more PPV5A peptides and a carrier molecule with a physiologically-acceptable vehicle such as a pharmaceutically- or veterinary-acceptable carrier, adjuvant, or combination thereof.
  • a physiologically-acceptable vehicle such as a pharmaceutically- or veterinary-acceptable carrier, adjuvant, or combination thereof.
  • the invention provides a method of diagnosing a PPV5A infection in a subject. That method comprises providing one or more PPV5A peptides; contacting the one or more PPV5A peptides with a sample obtained from the subject; and identifying the subject as having a PPV5A infection if an antibody capable of binding the one or more PPV5A peptides is detected in the sample.
  • the invention provides a method of ascertaining that a subject has been previously exposed to a PPV5A infection and is able to express an immune response to PPV5A. That method comprises providing one or more PPV5A peptides; contacting the one or more PPV5A peptides with a sample obtained from the subject; and identifying the subject as having a PPV5A infection if an antibody capable of binding the one or more PPV5A peptides is detected in the sample.
  • kits that comprise an immunogenic composition that comprises one or more PPV5A peptides, preferably together with a carrier molecule; a container for packaging the immunogenic composition; a set of printed instructions; and a dispenser capable of administering the immunogenic composition to an animal.
  • the one or more PPV5A peptides and the carrier molecule may be packaged as a conjugate or as separate compounds.
  • a means of conjugating the one or more PPV5A peptides and carrier molecule, as well as appropriate printed instructions is also supplied.
  • kits for vaccinating an animal comprising a set of printed instructions; a dispenser capable of administering the immunogenic composition provided herewith comprising one or more PPV5A peptides to an animal; and wherein at least one of PPV5A peptides effectively immunizes the animal against at least one disease associated with PPV5A infection.
  • the one or more PPV5A peptides are selected from those provided herewith.
  • Kits of the invention may further comprise a veterinary acceptable carrier, adjuvant, or combination thereof.
  • the dispenser in a kit of the invention is capable of dispensing its contents as droplets; and the immunogenic composition comprises the PPV5A peptides as provided herewith included in the kit is capable of reducing the severity of at least one clinical sign of a PPV5A infection when administered intranasally, orally, intradermally, or intramuscularly to an animal.
  • the severity of a clinical sign is reduced by at least 10% preferably by at least 20%, even more preferred by at least 30%, even more preferred by at least 50%, even more preferred by at least 70%, most preferred by at least 100% as compared to an untreated, infected animal.
  • Methods for the treatment or prophylaxis of infections caused by PPV5A are also disclosed.
  • the method comprises administering an effective amount of the immunogenic composition of the present invention to a subject, wherein said treatment or prophylaxis is selected from the group consisting of reducing signs of PPV5A infection, reducing the severity of or incidence of clinical signs of PPV5A infection, reducing the mortality of subjects from PPV5A infection, and combinations thereof.
  • compositions of the invention further comprise a veterinary-acceptable carrier, adjuvant, or combination thereof.
  • Such compositions may be used as a vaccine and comprise one or more additional attenuated vaccines, inactivated vaccines, or combinations thereof.
  • Such vaccines elicit a protective immunological response against at least one disease associated with viruses selected from the group consisting of porcine parvoviruses 1, 2, 3, 4, 5A, 5B, other porcine parvovirus species, other porcine pathogenic viruses and bacteria, and combinations thereof.
  • porcine circovirus type 2 e.g., Ingelvac® CircoFLEX, Ingelvac® CircoFLEX-MycoFLEX
  • porcine reproductive and respiratory syndrome virus e.g., Ingelvac® PRRS ATP, Ingelvac® PRRSV MLV
  • porcine parvovirus e.g., ReproCyc® PRRSV-PLE
  • Mycoplasma e.g., Ingelvac® MycoFLEX
  • porcine circovirus type 2 e.g., Ingelvac® CircoFLEX, Ingelvac® CircoFLEX-MycoFLEX
  • porcine reproductive and respiratory syndrome virus e.g., Ingelvac® PRRS ATP, Ingelvac® PRRSV MLV
  • porcine parvovirus e.g., ReproCyc® PRRSV-PLE
  • Mycoplasma e.g., Ingelvac® MycoFLEX
  • compositions used herein may incorporate known injectable, physiologically acceptable sterile solutions.
  • aqueous isotonic solutions e.g. saline or plasma protein solutions
  • the immunogenic and vaccine compositions of the present invention can include pharmaceutical- or veterinary-acceptable carriers, diluents, isotonic agents, stabilizers, or adjuvants.
  • Methods of the invention may also comprise admixing a composition of the invention with a veterinarily acceptable carrier, adjuvant, or combination thereof.
  • a veterinarily acceptable carrier for example, a benzyl alcohol, benzyl ether, benzyl ether, benzyl ether, benzyl ether, benzyl ether, benzyl ether, benzyl ether, benzyl ether, sulfate, sulfate, sulfate, or combination thereof.
  • the invention also provides a method of reducing the severity of an ongoing PPV5A infection in an animal by administration of a composition to the animal.
  • the composition may include an attenuated viral culture or one or more PPV5A peptides in combination with an acceptable veterinary carrier.
  • compositions of the invention may also be administered in two or more doses, as well as, by other routes of administration.
  • routes of administration include subcutaneously, intracutaneously, intravenously, intravascularly, intraarterially, intraperitnoeally, intrathecally, intratracheally, intracutaneously, intracardially, intralobally, intramedullarly, intrapulmonarily, or intravaginally.
  • the compositions according to the invention may be administered once or several times, also intermittently, for instance on a daily basis for several days, weeks or months and in different dosages.
  • kits for vaccinating an animal comprising a set of printed instructions; a dispenser capable of administering a vaccine to an animal; and at least one isolate from a cell culture, including but not limited to a bacterial, fungal, insect or mammalian cell culture that effectively immunizes the animal against at least one disease associated with PPV5A, other parvovirus strains, other pathogens, and/or a combination thereof.
  • Kits of the invention may further comprise a veterinary-acceptable carrier, adjuvant, or combination thereof.
  • the dispenser in a kit of the invention is capable of dispensing its contents as droplets; and the isolate included in the kit is capable of reducing the severity of at least one clinical sign of a PPV5A infection when administered intranasally, orally, intradermally, or intramuscularly to an animal.
  • the isolate is also capable of reducing the severity of at least one clinical sign of a PPV5A infection.
  • the severity of a clinical sign is reduced by at least 10% as compared to an untreated, infected animal.
  • FIG. 1 shows the nucleic acid sequence of PPV5A (SEQ ID NO:1).
  • FIG. 2 shows the protein sequence of the PPV5A replicase (SEQ ID NO:2).
  • FIG. 3 shows the protein sequence of the PPV5A open reading frame (ORF) protein (SEQ ID NO:3).
  • FIG. 4 shows the protein sequence of the PPV5A capsid protein (SEQ ID NO:4).
  • FIG. 5 shows pair-wise amino acid identity comparisons of the protein sequences of the PPV5A capsid protein and numerous other viral sequences. References for the viral sequences are listed in Table 1:
  • FIG. 6 shows a phylogenetic analysis of VP1/CAP region of PPV5A as compared with other viral VP1 and capsid proteins listed in Table 1.
  • FIG. 7 shows identities of the PPV5A capsid protein (residues 55-792 of SEQ ID NO:4) to the closest related protein of PPV4 (GenBank accession #AFM73871 (SEQ ID NO: 5)), showing a sequence identity of 40% (310/774).
  • FIG. 8 shows identities of the PPV5A replicase protein (residues 15-516 of SEQ ID NO:2) to the closest related protein of PPV4 (GenBank accession #ADB20210 (SEQ ID NO: 11)), showing a sequence identity of 58% (292/504).
  • the invention provides nucleic acids and fragments thereof, polypeptides and immunologically-effective fragments thereof, vaccines, immunologically-effective preparations, antibodies, diagnostic assays and kits, and methods of making and using said compositions and preparations, related to the herein-disclosed novel porcine parvovirus 5A and variants thereof.
  • “Protection against disease,” “protective immunity,” “functional immunity” and similar phrases means a response against a disease or condition generated by administration of one or more therapeutic compositions of the invention, or a combination thereof, that results in fewer deleterious effects than would be expected in a non-immunized subject that has been exposed to disease or infection. That is, the severity of the deleterious effects of the infection are lessened in a vaccinated subject. Infection may be reduced, slowed, or possibly fully prevented, in a vaccinated subject.
  • complete prevention of infection is meant, it is specifically stated. If complete prevention is not stated then the term includes partial prevention.
  • “reduction of the incidence and/or severity of clinical signs” or “reduction of clinical symptoms” means, but is not limited to, reducing the number of infected subjects in a group, reducing or eliminating the number of subjects exhibiting clinical signs of infection, or reducing the severity of any clinical signs that are present in one or more subjects, in comparison to wild-type infection.
  • these clinical signs are reduced in one or more subjects receiving the therapeutic composition of the present invention by at least 10% in comparison to subjects not receiving the composition and that become infected. More preferably clinical signs are reduced in subjects receiving a composition of the present invention by at least 20%, preferably by at least 30%, more preferably by at least 40%, and even more preferably by at least 50%.
  • the term “increased protection” herein means, but is not limited to, a significant reduction of one or more clinical symptoms which are associated with infection by an infectious agent, preferably PPV5A, in a vaccinated group of subjects vs. a non-vaccinated control group of subjects.
  • the term “significant reduction of clinical symptoms” means, but is not limited to, the frequency in the incidence of at least one clinical symptom in the vaccinated group of subjects is at least 10%, preferably 20%, more preferably 30%, even more preferably 50%, and even more preferably 70% lower than in the non-vaccinated control group after the challenge the infectious agent.
  • Long-lasting protection shall refer to “improved efficacy” that persists for at least 3 weeks, but more preferably at least 3 months, still more preferably at least 6 months. In the case of livestock, it is most preferred that the long lasting protection shall persist until the average age at which animals are marketed for meat.
  • an “immunogenic or immunological composition” refers to a composition of matter that comprises at least one PPV5A protein or polypeptide, or immunogenic portion thereof, that elicits an immunological response in the host of a cellular or antibody-mediated immune response to the composition.
  • an immunogenic composition induces an immune response and, more preferably, confers protective immunity against one or more of the clinical signs of a PPV5A infection.
  • an “immunogenic” PPV5A polypeptide, or “antigen” as used herein refer to a polypeptide or protein that elicits an immunological response as described herein.
  • An “immunogenic” PPV5A protein or polypeptide includes the full-length sequence of any of the coding sequences identified herein or analogs or immunogenic fragments thereof.
  • the term “immunogenic fragment” or “immunogenic portion” refers to a fragment or truncated and/or substituted form of an amino acid sequence of a PPV5A protein that includes one or more epitopes and thus elicits the immunological response described herein.
  • such truncated and/or substituted forms, or fragments will comprise or encode at least six contiguous amino acids from the full-length protein, e.g., the capsid protein. More preferably, the truncated or substituted forms, or fragments will have at least 10, more preferably at least 15, and still more preferably at least 19, and even more preferably 30 contiguous amino acids from the full-length protein, e.g., the capsid protein.
  • epitope means a segment or fragment of a composition of matter, e.g., a protein or polypeptide, which is recognized by the immune system, specifically by antibodies, B cells, or T cells.
  • the epitope is generally a fragment or fragments of a polypeptide sequence of a viral protein.
  • Such fragments can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, N.J.
  • linear epitopes may be determined by concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports.
  • Such techniques are known and described in the art, see e.g., U.S. Pat. No. 4,708,871; Geysen et al. (1984) Proc. Natl.
  • conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and two-dimensional nuclear magnetic resonance. See Epitope Mapping Protocols, supra.
  • Synthetic antigens are also included within the definition, for example, polyepitopes, flanking epitopes, and other recombinant or synthetically derived antigens. See, e.g., Bergmann et al. (1993) Eur. J. Immunol. 23:2777-2781; Bergmann et al.
  • an “immune response” or “immunological response” means, but is not limited to, the development of a cellular and/or antibody-mediated immune response to the composition or vaccine of interest.
  • an immune or immunological response includes, but is not limited to, one or more of the following effects: the production or activation of antibodies, B cells, helper T cells, suppressor T cells, and/or cytotoxic T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest.
  • the host will display either a therapeutic or a protective immunological (memory) response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced.
  • Such protection will be demonstrated by either a reduction in number of symptoms, severity of symptoms, or the lack of one or more of the symptoms associated with the infection of the pathogen, a delay in the of onset of viremia, reduced viral persistence, a reduction in the overall viral load and/or a reduction of viral excretion.
  • specifically immunoreactive refers to an immunoreactive protein or polypeptide that recognizes an antigen characteristic of PPV5A infection but does not react with an antigen characteristic of a strict challenge control.
  • various immunoassays ELISA, IFA, WesternBlot
  • ELISA, IFA, WesternBlot immunoassays
  • the protein would also be tested in various immunoassays against material containing proteins related to the expression method (Baculovirus, Sf9 cells, etc.).
  • a pharmaceutical- or veterinary-acceptable carrier or “excipient” includes any and all solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like.
  • stabilizing agents for use in the present invention include stabilizers for lyophilization or freeze-drying.
  • the immunogenic composition of the present invention contains an adjuvant.
  • adjuvants can include aluminum hydroxide and aluminum phosphate, saponins e.g., Quil A, QS-21 (Cambridge Biotech Inc., Cambridge, Mass.), GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham, Ala.), water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion.
  • the emulsion can be based in particular on light liquid paraffin oil (European Pharmacopea type); isoprenoid oil such as squalane or squalene; oil resulting from the oligomerization of alkenes, in particular of isobutene or decene; esters of acids or of alcohols containing a linear alkyl group, more particularly plant oils, ethyl oleate, propylene glycol di-(caprylate/caprate), glyceryl tri-(caprylate/caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, in particular isostearic acid esters.
  • light liquid paraffin oil European Pharmacopea type
  • isoprenoid oil such as squalane or squalene
  • oil resulting from the oligomerization of alkenes in particular of isobutene or decene
  • the oil is used in combination with emulsifiers to form the emulsion.
  • the emulsifiers are preferably nonionic surfactants, in particular esters of sorbitan, of mannide (e.g. anhydromannitol oleate), of glycol, of polyglycerol, of propylene glycol and of oleic, isostearic, ricinoleic or hydroxystearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in particular the Pluronic products, especially L121.
  • mannide e.g. anhydromannitol oleate
  • glycol of polyglycerol
  • propylene glycol and of oleic isostearic, ricinoleic or hydroxystearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in particular the Pluronic products
  • Vaccine 15:564-570 exemplary adjuvants are the SPT emulsion described on page 147 of “Vaccine Design, The Subunit and Adjuvant Approach” edited by M. Powell and M. Newman, Plenum Press, 1995, and the emulsion MF59 described on page 183 of this same book.
  • an adjuvant is a compound chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative.
  • Advantageous adjuvant compounds are the polymers of acrylic or methacrylic acid which are cross-linked, especially with polyalkenyl ethers of sugars or polyalcohols. These compounds are known by the term carbomer (Phameuropa Vol. 8, No. 2, June 1996). Persons skilled in the art can also refer to U.S. Pat. No.
  • 2,909,462 which describes such acrylic polymers cross-linked with a polyhydroxylated compound having at least 3 hydroxyl groups, preferably not more than 8, the hydrogen atoms of at least three hydroxyls being replaced by unsaturated aliphatic radicals having at least 2 carbon atoms.
  • the preferred radicals are those containing from 2 to 4 carbon atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups.
  • the unsaturated radicals may themselves contain other substituents, such as methyl.
  • the products sold under the name Carbopol; (BF Goodrich, Ohio, USA) are particularly appropriate. They are cross-linked with an allyl sucrose or with allyl pentaerythritol.
  • Carbopol 974P, 934P and 971P there may be mentioned Carbopol 974P, 934P and 971P. Most preferred is the use of Cabopol 971P.
  • copolymers of maleic anhydride and alkenyl derivative are the copolymers EMA (Monsanto), which are copolymers of maleic anhydride and ethylene. The dissolution of these polymers in water leads to an acid solution that will be neutralized, preferably to physiological pH, in order to give the adjuvant solution into which the immunogenic, immunological or vaccine composition itself will be incorporated.
  • Suitable adjuvants include, but are not limited to, the RIBI adjuvant system (Ribi Inc.), Block co-polymer (CytRx, Atlanta, Ga.), SAF-M (Chiron, Emeryville, Calif.), monophosphoryl lipid A, Avridine lipid-amine adjuvant, heat-labile enterotoxin from E. coli (recombinant or otherwise), cholera toxin, IMS 1314 or muramyl dipeptide, or naturally occurring or recombinant cytokines or analogs thereof or stimulants of endogenous cytokine release, among many others.
  • an adjuvant can be added in an amount of about 100 ⁇ g to about 10 mg per dose, preferably in an amount of about 500 ⁇ g to about 5 mg per dose, more preferably in an amount of about 750 ⁇ g to about 2.5 mg per dose, and most preferably in an amount of about 1 mg per dose.
  • the adjuvant may be at a concentration of about 0.01 to 50%, preferably at a concentration of about 2% to 30%, more preferably at a concentration of about 5% to 25%, still more preferably at a concentration of about 7% to 22%, and most preferably at a concentration of 10% to 20% by volume of the final product.
  • “Diluents” can include water, saline, dextrose, ethanol, glycerol, and the like.
  • Isotonic agents can include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others.
  • Stabilizers include albumin and alkali salts of ethylendiamintetracetic acid, among others.
  • isolated means altered “by the hand of man” from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both.
  • a polynucleotide or polypeptide naturally present in a living organism is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.
  • Safety refers to the absence of adverse consequences in a vaccinated animal following vaccination, including but not limited to: potential reversion of a live viral-based vaccine to virulence, clinically significant side effects such as persistent, systemic illness or unacceptable inflammation at the site of vaccine administration.
  • vaccination or “vaccinating” or variants thereof, as used herein means, but is not limited to, a process which includes the administration of an immunogenic composition of the invention that, when administered to an animal, elicits, or is able to elicit—directly or indirectly—an immune response in the animal against PPV5A.
  • “Mortality”, in the context of the present invention, refers to death caused by PPV5A infection, and/or co-infections with other organisms which are potentiated by PPV5A infections, and includes the situation where the infection is so severe that an animal is euthanized to prevent suffering and provide a humane ending to its life.
  • Attenuation means reducing the virulence of a pathogen.
  • attenuation is synonymous with “avirulent.”
  • an attenuated virus is one in which the virulence has been reduced so that it does not cause clinical signs of a PPV5A infection but is capable of inducing an immune response in the target mammal, but may also mean that the clinical signs are reduced in incidence or severity in animals infected with the attenuated PPV5A in comparison with a “control group” of animals infected with non-attenuated PPV5A and not receiving the attenuated virus.
  • an attenuated, avirulent PPV5A strain is one that suitable for incorporation into an immunogenic composition comprising a modified live PPV5A virus.
  • “Killed” or “inactivated” means treated with a physical or chemical agent which renders the PPV5A virus dead and/or otherwise incapable of reproduction.
  • PPV5A may be killed by conventional means, such as, for example, heat, radiation or psoralen in the presence of ultraviolet light.
  • PPV5A can be inactivated by conventional means such as, for example, through chemical inactivation using one or more chemical inactivating agents including, but not limited to, one or more of binary ethyleneimine (BEI), beta-propiolactone, formalin, gluteraldehyde, and/or sodium dodecyl sulfate.
  • BEI binary ethyleneimine
  • beta-propiolactone formalin
  • gluteraldehyde gluteraldehyde
  • sodium dodecyl sulfate sodium dodecyl sulfate
  • Antigens from PPV5A for use in the vaccine compositions of the present invention can thus be in the form of a whole virus which is a modified and/or attenuated live viral preparation or a killed or inactivated viral preparation, inter alia.
  • Antibodies as used herein includes anti-PPV5A antibodies, e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, humanized, human, porcine, and CDR-grafted antibodies, including compounds which include CDR sequences which specifically recognize a PPV5A polypeptide of the invention.
  • the term “specific for” indicates that the variable regions of the antibodies of the invention recognize and bind a PPV5A polypeptide exclusively (i.e., are able to distinguish a single PPV5A polypeptide from related polypeptides despite sequence identity, homology, or similarity found in the family of polypeptides), and which are permitted (optionally) to interact with other proteins (for example, S.
  • aureus protein A or other antibodies in ELISA techniques through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the antibody molecule.
  • Screening assays to determine binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow et al. (Eds), Antibodies A Laboratory Manual: Cold Spring Harbor Laboratory; Cold Spring Harbor, N.Y. (1988), Chapter 6.
  • Antibodies that recognize and bind fragments of the PPV5A polypeptides of the invention are also contemplated, provided that the antibodies are first and foremost specific for, as defined above, a PPV5A polypeptide of the invention from which the fragment was derived.
  • antibody refers to an immunoglobulin molecule that can bind to a specific antigen as the result of an immune response to that antigen.
  • Immunoglobulins are serum proteins composed of “light” and “heavy” polypeptide chains having “constant” and “variable” regions and are divided into classes (e.g., IgA, IgD, IgE, IgG, and IgM) based on the composition of the constant regions.
  • Antibodies can exist in a variety of forms including, for example, as, Fv, Fab′, F(ab′)2, as well as in single chains, and include synthetic polypeptides that contain all or part of one or more antibody single chain polypeptide sequences.
  • an effective dose means, but is not limited to, an amount of antigen that elicits, or is able to elicit, an immune response that yields a reduction of clinical symptoms in an animal to which the antigen is administered.
  • the term “effective amount” means, in the context of a composition, an amount of an immunogenic composition capable of inducing an immune response that reduces the incidence of or lessens the severity of infection or incident of disease in an animal.
  • an effective amount an attenuated live virus preparation is monitored by the median tissue culture infective dose (TCID50), i.e. the amount of a pathogenic agent that will produce pathological change in 50% of inoculated and susceptible cell cultures.
  • TCID50 median tissue culture infective dose
  • the effective amount refers to the relative antigen content (RAC), i.e. the inclusion level of antigen per effective dose.
  • the term “effective amount” refers to the amount of a therapy which is sufficient to reduce or ameliorate the severity or duration of a disease or disorder, or one or more symptoms thereof, prevent the advancement of a disease or disorder, cause the regression of a disease or disorder, prevent the recurrence, development, onset, or progression of one or more symptoms associated with a disease or disorder, or enhance or improve the prophylaxis or treatment of another therapy or therapeutic agent.
  • Sequence identity refers to a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, namely a reference sequence and a given sequence to be compared with the reference sequence. Sequence identity is determined by comparing the given sequence to the reference sequence after the sequences have been optimally aligned to produce the highest degree of sequence similarity, as determined by the match between strings of such sequences, with gaps introduced if necessary. Upon such alignment, sequence identity is ascertained on a position-by-position basis, e.g., the sequences are “identical” at a particular position if at that position, the nucleotides or amino acid residues are identical.
  • Sequence identity can be readily calculated by known methods, including but not limited to, those described in Computational Molecular Biology, Lesk, A. N., ed., Oxford University Press, New York (1988), Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology, von Heinge, G., Academic Press (1987); Sequence Analysis Primer, Gribskov, M.
  • Preferred methods to determine the sequence identity are designed to give the largest match between the sequences tested. Methods to determine sequence identity are codified in publicly available computer programs which determine sequence identity between given sequences. Examples of such programs include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research, 12(1):387 (1984)), BLASTP, BLASTN and BLASTX (Altschul, S. F. et al., J.
  • BLASTX program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al., NCVI NLM NIH Bethesda, Md. 20894, Altschul, S. F. et al., J. Molec. Biol., 215:403-410 (1990), the teachings of which are incorporated herein by reference). These programs optimally align sequences using default gap weights in order to produce the highest level of sequence identity between the given and reference sequences.
  • nucleotide sequence having at least, for example, 85%, preferably 90%, even more preferably 95% “sequence identity” to a reference nucleotide sequence it is intended that the nucleotide sequence of the given polynucleotide is identical to the reference sequence except that the given polynucleotide sequence may include up to 15, preferably up to 10, even more preferably up to 5 point mutations per each 100 nucleotides of the reference nucleotide sequence.
  • a polynucleotide having a nucleotide sequence having at least 85%, preferably 90%, even more preferably 95% identity relative to the reference nucleotide sequence up to 15%, preferably 10%, even more preferably 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 15%, preferably 10%, even more preferably 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
  • mutations of the reference sequence may occur at the 5′ or 3′ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
  • a polypeptide having a given amino acid sequence having at least, for example, 85%, preferably 90%, even more preferably 95% sequence identity to a reference amino acid sequence it is intended that the given amino acid sequence of the polypeptide is identical to the reference sequence except that the given polypeptide sequence may include up to 15, preferably up to 10, even more preferably up to 5 amino acid alterations per each 100 amino acids of the reference amino acid sequence.
  • a given polypeptide sequence having at least 85%, preferably 90%, even more preferably 95% sequence identity with a reference amino acid sequence up to 15%, preferably up to 10%, even more preferably up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 15%, preferably up to 10%, even more preferably up to 5% of the total number of amino acid residues in the reference sequence may be inserted into the reference sequence.
  • These alterations of the reference sequence may occur at the amino or the carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in the one or more contiguous groups within the reference sequence.
  • residue positions which are not identical differ by conservative amino acid substitutions. However, conservative substitutions are not included as a match when determining sequence identity.
  • Sequence homology refers to a method of determining the relatedness of two sequences. To determine sequence homology, two or more sequences are optimally aligned, and gaps are introduced if necessary. However, in contrast to “sequence identity,” conservative amino acid substitutions are also counted as a match when determining sequence homology.
  • the homologous sequence comprises at least a stretch of 50, even more preferred of 100, even more preferred of 250, even more preferred of 500 nucleotides encoding homologous amino acids.
  • a “conservative substitution” refers to the substitution of an amino acid residue with another amino acid residue having similar characteristics or properties including size, hydrophobicity, etc., such that the overall functionality does not change significantly. It can also mean a nucleotide substitution that results in a conservative amino acid substitution.
  • the carrier molecules to which the PPV5A proteins or peptides of the invention can be conjugated or covalently linked are preferably those described above.
  • Preferred carriers for animal use are bovine serum albumin and Keyhole Limpet Hemocyanin.
  • the carrier protein itself is an immunogen.
  • the PPV5A proteins or peptides of the invention may be covalently coupled to the carrier by any convenient method known to the art. While use of a symmetric linker such as adipic acid dihydrazide, as described by Schneerson et al, J. Experimental Medicine, 152, 361-376 (1980), or a heterobifunctional linker such as N-succinimidyl 3-(2-pyridyldithio)propionate as described by Fattom et al, Infection and Immunity, 56, 2292-2298 (1988) are within the scope of the invention, it is preferred to avoid the use of any linker but instead couple a PPV5A peptide of the invention directly to the carrier molecule. Such coupling may be achieved by means of reductive amination as described by Landi et al J. Immunology, 127, 1011-1019 (1981).
  • the size of the immunogenic composition is variable and dependent upon the chosen PPV5A protein(s) or peptide(s) and the method of coupling of the PPV5A protein(s) or peptide(s) to the carrier. Therefore, it can be as small as 1,000 daltons (10 3 ) or greater than 10 6 daltons.
  • the molecular weight of the PPV5A protein(s) or peptide(s) is usually within the range of 5,000 to 500,000 or more; e.g., for the capsid protein of SEQ ID NO:4, the molecular weight is predicted to be approximately 80,000 daltons, which is predicted to form virus like particles (VLP) comprised of 60 monomeric proteins.
  • VLP virus like particles
  • Carrier molecules i.e. peptides, derivatives and analogs thereof, and peptide mimetics that specifically bind a PPV5A protein or peptide of the invention can be produced by various methods known in the art, including, but not limited to solid-phase synthesis or by solution (Nakanishi et al., 1993, Gene 137:51-56; Merrifield, 1963, J. Am. Chem. Soc. 15:2149-2154; Neurath, H. et al., Eds., The Proteins, Vol II, 3d Ed., p. 105-237, Academic Press, New York, N.Y. (1976), incorporated herein in their entirety by reference).
  • the PPV5A proteins or peptides of the invention or the antibodies or binding portions thereof of the present invention may be administered in injectable dosages by solution or suspension of in a diluent with a pharmaceutical or veterinary carrier.
  • Safety and efficacy of such molecules are determined by standard procedures in cell cultures or experimental animals as described and regulated by the Center for Veterinary Biologics (CVB). Toxicity and therapeutic efficacy of such molecules can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population).
  • CVB Center for Veterinary Biologics
  • the vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from immuno-conjugation of multiple PPV5A proteins or peptides with a carrier molecule.
  • the PPV5A protein or peptide compositions comprise an effective immunizing amount of the immunogenic conjugate, preferably in combination with an immunostimulant; and a physiologically acceptable vehicle.
  • immunostimulant is intended to encompass any compound or composition which has the ability to enhance the activity of the immune system, whether it is a specific potentiating effect in combination with a specific antigen, or simply an independent effect upon the activity of one or more elements of the immune response.
  • Immunostimulant compounds include but are not limited to mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, and MDP. Methods of utilizing these materials are known in the art, and it is well within the ability of the skilled artisan to determine an optimum amount of stimulant for a given vaccine. More than one immunostimulant may be used in a given formulation. The immunogen may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers for use in a vaccine formulation.
  • compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration preferably for administration to a mammal, especially a pig.
  • immunogenic compositions provided herewith and which contain one or more PPV5A proteins or peptides may also comprise one or more adjuvants.
  • the adjuvant may be purified by any of the techniques described previously or known in the art.
  • the preferred purification technique is silica gel chromatography, in particular the “flash” (rapid) chromatographic technique, as described by W. Clark Still et al, J. Organic Chemistry, 43, 2923-2925 (1978).
  • other chromatographic methods including HPLC, may be used for purification of the adjuvant.
  • Crystallization may also be used to purify the adjuvant. In some cases, no purification is required as a product of analytical purity is obtained directly from the synthesis.
  • the vaccine compositions of the invention are prepared by physically mixing the adjuvant with the PPV5A protein(s) or peptide(s) under appropriate sterile conditions in accordance with known techniques to produce the adjuvanted composition. Complexation of the PPV5A proteins(s) or peptide(s) and the adjuvant is facilitated by the existence of a net negative charge on the conjugate which is electrostatically attracted to the positive charge present on the long chain alkyl compound adjuvant.
  • the vaccine compositions of this invention may be formulated using techniques similar to those used for other pharmaceutical polypeptide compositions.
  • the adjuvant and PPV5A protein(s) or peptide(s), preferably conjugated to carrier molecule and/or admixed with an adjuvant may be stored in lyophilized form and reconstituted in a physiologically acceptable vehicle to form a suspension prior to administration.
  • the adjuvant and conjugate may be stored in the vehicle.
  • Preferred vehicles are sterile solutions, in particular, sterile buffer solutions, such as phosphate buffered saline. Any method of combining the adjuvant and the conjugate in the vehicle such that improved immunological effectiveness of the immunogenic composition is appropriate.
  • the volume of a single dose of the vaccine of this invention may vary but will be generally within the ranges commonly employed in conventional vaccines.
  • the volume of a single dose is preferably between about 0.1 ml and about 3 ml, preferably between about 0.2 ml and about 1.5 ml, more preferably about 1.0 ml at the concentrations of conjugate and adjuvant noted above.
  • the vaccine compositions of the invention may be administered by any convenient means.
  • Immunogenic conjugates comprising a PPV5A protein(s) or peptide(s) coupled to a carrier molecule can be used as vaccines for immunization against one or more serotypes of PPV5A.
  • the vaccines comprising the immunogenic conjugate in a physiologically acceptable vehicle, are useful in a method of immunizing animals, preferably swine, for treatment or prevention of infections by PPV5A.
  • Antibodies generated against immunogenic conjugates of the present invention by immunization with an immunogenic conjugate can be used in passive immunotherapy and generation of antiidiotypic antibodies for treating or preventing infections of PPV5A.
  • the subject to which the composition is administered is preferably an animal, including but not limited to cows, horses, sheep, pigs, poultry (e.g., chickens), goats, cats, dogs, hamsters, mice and rats; most preferably pigs.
  • cows horses, sheep, pigs, poultry (e.g., chickens), goats, cats, dogs, hamsters, mice and rats; most preferably pigs.
  • the formulations of the invention comprise an effective immunizing amount of one or more immunogenic compositions or antibodies thereto and a physiologically acceptable vehicle.
  • Vaccines comprise an effective immunizing amount of one or more immunogenic compositions and a physiologically acceptable vehicle.
  • the formulation should suit the mode of administration.
  • the immunogenic composition can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • the immunogenic composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
  • the compounds described herein can be administered to a subject at therapeutically effective doses to treat PPV5A-associated diseases.
  • the dosage will depend upon the host receiving the vaccine as well as factors such as the size, weight, and age of the host.
  • an effective immunizing amount is that amount sufficient to treat or prevent a PPV5A infectious disease in a subject.
  • Effective doses may also be extrapolated from dose-response curves derived from animal model test systems and can vary from 0.1 mg/kg to 20 mg/kg, preferably 1 mg/kg to 10 mg/kg.
  • Immunogenicity of a composition can be determined by monitoring the immune response of test subjects following immunization with the composition by use of any immunoassay known in the art. Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response.
  • Test subjects may include animals such as pigs, mice, hamsters, dogs, cats, rabbits, cows, horses, sheep, and poultry (e.g. chickens, ducks, geese, and turkeys).
  • the immune response of the test subjects can be analyzed by various approaches such as: the reactivity of the resultant immune serum to the immunogenic conjugate, as assayed by known techniques, e.g., enzyme linked immunosorbent assay (ELISA), immunoblots, immunoprecipitations, etc.; or, by protection of immunized hosts from infection by the pathogen and/or attenuation of symptoms due to infection by the pathogen in immunized hosts as determined by any method known in the art, for assaying the levels of an infectious disease agent, e.g., quantitative PCR, virus isolation or other technique known in the art.
  • the levels of the infectious disease agent may also be determined by measuring the levels of the antigen against which the immunoglobulin was directed. A decrease in the levels of the infectious disease agent or an amelioration of the symptoms of the infectious disease indicates that the composition is effective.
  • the therapeutics of the invention can be tested in vitro for the desired therapeutic or prophylactic activity, prior to in vivo use in animals.
  • in vitro assays that can be used to determine whether administration of a specific therapeutic is indicated include in vitro cell culture assays in which appropriate cells from a cell line or cells cultured from a subject having a particular disease or disorder are exposed to or otherwise administered a therapeutic, and the effect of the therapeutic on the cells is observed.
  • the therapeutic may be assayed by contacting the therapeutic to cells (either cultured from a subject or from a cultured cell line) that are susceptible to infection by the infectious disease agent but that are not infected with the infectious disease agent, exposing the cells to the infectious disease agent, and then determining whether the infection rate of cells contacted with the therapeutic was lower than the infection rate of cells not contacted with the therapeutic.
  • Infection of cells with an infectious disease agent may be assayed by any method known in the art.
  • the therapeutic can be assessed by measuring the level of the molecule against which the antibody is directed in the animal model subject at suitable time intervals before, during, or after therapy. Any change or absence of change in the amount of the molecule can be identified and correlated with the effect of the treatment on the subject.
  • the level of the molecule can be determined by any method known in the art.
  • any binding assay known in the art can be used to assess the binding between the resulting antibody and the particular molecule. These assays may also be performed to select antibodies that exhibit a higher affinity or specificity for the particular antigen.
  • Antibodies, or binding portions thereof, resulting from the use of native PPV5A, attenuated virus, proteins or peptides of the present invention are useful for detecting in a sample the presence of PPV5A.
  • This detection method comprises the steps of providing an isolated antibody or binding portion thereof raised against a native PPV5A, attenuated virus, protein or peptide of the invention, adding to the isolated antibody or binding portion thereof a sample suspected of containing a quantity of PPV5A virus and detecting the presence of a complex comprising the isolated antibody or binding portion thereof bound to PPV5A virus.
  • the antibodies or binding portions thereof of the present invention are also useful for detecting in a sample the presence of a PPV5A protein or peptide.
  • This detection method comprises the steps of providing an isolated antibody or binding portion thereof raised against native PPV5A, attenuated virus, protein or peptide, adding to the isolated antibody or binding portion thereof a sample suspected of containing a quantity of the PPV5A protein or peptide, and detecting the presence of a complex comprising the isolated antibody or binding portion thereof bound to the PPV5A protein or peptide.
  • Immunoglobulins particularly antibodies, (and functionally active fragments thereof) that bind a specific molecule that is a member of a binding pair may be used as diagnostics and prognostics, as described herein.
  • the present invention provides the measurement of a member of the binding pair, and the uses of such measurements in clinical applications.
  • the immunoglobulins in the present invention may be used, for example, in the detection of an antigen in a biological sample whereby subjects may be tested for aberrant levels of the molecule to which the immunoglobulin binds, and/or for the presence of abnormal forms of such molecules.
  • antibodies of this invention may also be included as a reagent in a kit for use in a diagnostic or prognostic technique.
  • an antibody of the invention that immunospecifically binds to a PPV5A native or attenuated virus, protein or peptide may be used to diagnose, prognose or screen for a PPV5A infection.
  • the invention provides a method of diagnosing or screening for the presence of a PPV5A infection or immunity thereto, comprising measuring in a subject the level of immunospecific binding of an antibody to a sample derived from the subject, in which the antibody immunospecifically binds a PPV5A protein or peptide in which an increase in the level of said immunospecific binding, relative to the level of said immunospecific binding in an analogous sample from a subject not having the infectious disease agent, indicates the presence of PPV5A.
  • Suitable assays to detect the presence of PPV5A peptides or antagonists thereof include but are not limited to ELISA, radioimmunoassay, gel-diffusion precipitation reaction assay, immunodiffusion assay, agglutination assay, fluorescent immunoassay, protein A immunoassay, or immunoelectrophoresis assay.
  • Immunoassays for the particular molecule will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cultured cells, in the presence of a detectably labeled antibody and detecting the bound antibody by any of a number of techniques wellknown in the art.
  • a sample such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cultured cells.
  • binding activity of a given antibody may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.
  • kits for the detection or measurement of PPV5A are provided, that comprise in one or more containers an anti-PPV5A antibody, and, optionally, a labeled binding partner to the antibody.
  • the anti-PPV5A antibody can be labeled (with a detectable marker, e.g., a chemiluminescent, enzymatic, fluorescent, or radioactive moiety).
  • the present invention provides a diagnostic kit comprising, an anti-PPV5A antibody and a control immunoglobulin.
  • one of the foregoing compounds of the container can be detectably labeled.
  • a kit can optionally further comprise, in a container, a predetermined amount of a PPV5A virus, protein or peptide recognized by the antibody of the kit, for use as a standard or control.
  • compositions of the invention may also be administered in one, two or more doses, as well as, by other routes of administration.
  • routes of administration include subcutaneously, intracutaneously, intravenously, intravascularly, intraarterially, intraperitnoeally, intrathecally, intratracheally, intracardially, intralobally, intramedullarly, intrapulmonarily, and intravaginally.
  • the compositions according to the invention may be administered once or several times, also intermittently, for instance on a daily basis for several days, weeks or months and in different dosages.
  • Tissue homogenates from three pigs were received from an unusual outbreak investigation.
  • the clinical history on the farm was of 200 lb pigs with full body muscle tremors which were present upon rest but exaggerated during movement.
  • a viral agent based on microscopic lesions
  • Agent X a non-classical swine fever virus associated pestivirus
  • DNA and Protein Analysis DNA analysis of samples from affected pigs was conducted using high throughput sequencing from 454 Life Sciences (Branford, Conn.) (“454 technology”), performed by Operon (Huntsville, Ala.). Samples were enriched for viral sequences through nuclease treatment of viral particle protect nucleic acids followed by extraction, random amplification and high throughput sequencing; performed generally as described in Victoria et. al PLoS pathogen 2008 September 26; 4(9):e1000163.
  • Resultant sequences were initially characterized by BLASTx analysis as divergent members of the Parvoviridae family. Sequences were assembled using Sequencher software and the results of these DNA analyses coupled with targeted sequencing yielded the DNA sequence of SEQ ID NO:1, which is the putative complete coding sequence of the virus denoted as PPV5A. Further analysis of the DNA sequence using Sequencher software resulted in identification of three putative coding regions corresponding to those found in other parvovirus species, comprising the viral replicase (SEQ ID NO:2), an open reading frame “ORF3” (SEQ ID NO:3) and the viral capsid protein (SEQ ID NO:4).
  • DNA sequences were identified by 454 technology (viral metagenomics) in samples of lung homogenates of two unrelated pigs from different states.
  • BLASTn and BLASTx analysis revealed the closest identity to porcine parvovirus 4, with a maximum of 67% nucleotide identity in conserved regions of the replicase gene (REP), while the capsid (CAP) coding regions did not exhibit a discernible match at the nucleotide level.
  • the putative replicase protein exhibited ⁇ 60% amino acid identity and ⁇ 50% identity in the capsid protein.
  • the virus was denoted as a new species, porcine parvovirus 5A (PPV5A).
  • Pair-wise amino acid identities for both the putative replicase (REP) and capsid (VP1/CAP) proteins of multiple known viral species are shown in FIG. 5 .
  • PPV5A sequence identity to PPV4 the closest relative, with both REP and CAP ( ⁇ 60%/50%, respectively) supporting designation of PPV5A as a new species.
  • FIG. 6 Phylogenetic analysis ( FIG. 6 ) reveals the virus to be a novel species within the Parvoviridae family and parvovirus genus, based on the conserved region of the CAP protein. Similar results are achieved using the more conserved REP protein sequence (not shown).
  • PCR positive tissues e.g. spleen, brain, lung, intestine etc
  • the ground tissue is resuspended in 5-10 ml modified EMEM containing HEPES buffer and antibiotics and clarified to eliminate larger tissue masses.
  • the supernatants are collected and serially passed through various filters to eliminate most of the larger particles including bacteria.
  • fecal sample suspension and serum from PCR positive animals are also being processed by serial filtration for virus isolation.
  • Dilutions of the filtrate are treated with trypsin or left untreated and are adsorbed onto established and primary cell cultures (listed below) in 6-well plates at specific temperatures.
  • the inoculum is aspirated and replaced with 2 ml fresh maintenance medium.
  • the plates are then incubated at 33-37° C. in a 5% CO 2 atmosphere and are observed daily for cytopathic effects such as cell rounding, cell-cell fusion, sloughing, cell clustering etc as compared to mock (plain media) inoculated controls.
  • Potential positive wells are screened for virus growth/isolation by PCR.
  • ST swine testes
  • SK6 swine kidney
  • BHK-21 baby hamster kidney
  • VIDO R1 fetal porcine retina
  • PK-15 NADC porcine kidney
  • PK/WRL porcine kidney
  • HRT-180 human colorectal adenocarcinoma
  • Hep2 human epithelial
  • Vero Africann green monkey kidney
  • RK-13 rabbit kidney
  • Primary cell cultures useful in the process include: Embryonic porcine lung, kidney, testes, trachea, and intestine cultures, among others.
  • virus As the virus is isolated, it is purified by multiple rounds of plaque purification or limiting dilutions and amplified in larger quantities and generate stock cultures for animal experiments.
  • Inactivation is performed between about 35-39° C. and in the presence of 2 to 15 mM BEI, still more preferred in the presence of about 10 mM BEI. Inactivation is performed for at least 24 hours, up to 24 to 72 hours. An equivalent amount of an agent that neutralizes the inactivation agent within the solution is then added; e.g., sodium thiosulfate to an equivalent amount.
  • an agent that neutralizes the inactivation agent within the solution is then added; e.g., sodium thiosulfate to an equivalent amount.
  • An inactivated virus preparation is prepared in accordance with methods known in the art, e.g., as disclosed in Preuss, T., et al., Comparison of Two Different Methods for Inactivation of Viruses in Serum, CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, (1997), 504-508 or Bahnemann, H. G., Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine, VACCINE, (1990), 299-303.
  • the material is combined with a carrier preparation for final vaccine formulation.
  • An attenuated virus preparation is prepared in accordance with methods known in the art, e.g., as disclosed in Vaccine Protocols, 2nd edition; Robinson, Husdon, Cranage, eds, Humana Press 2003.
  • Vaccine Protocols 2nd edition
  • Robinson Husdon, Cranage, eds, Humana Press 2003.
  • . . . wild type viruses are extensively passaged in tissue culture/animal hosts until an acceptable balance is reached between loss of virulence and retention of immunogenicity . . . .”
  • Attenuated virus is purified by multiple rounds of plaque purification or limiting dilutions. PCR assays, deep sequencing or immunofluorescence assays are utilized to determine the specificity of the culture material.
  • An attenuated viral vaccine is prepared by combining a purified attenuated virus preparation with a carrier preparation.
  • the capsid protein of SEQ ID NO:4 was prepared by expression of the cloned SEQ ID NO:4, or fragments thereof, in various protein expression systems.
  • Baculovirus expression PPV5A capsid protein of SEQ ID NO:4 was expressed in a baculovirus expression system, generally in accordance with the methods disclosed in Kost et al. (6), 2012. The protein was found in low quantity within the insoluble fraction upon initial purification.
  • Methods to increase yield and solubility include, but are not limited to, use of alternative buffer conditions (e.g. urea or guanidine hydrochloride), alternative binding and purification conditions (e.g. cobalt or nickel affinity columns, anion or cation exchange columns), or alternative expression conditions (e.g. temperature, time, alternative cell lines).
  • alternative buffer conditions e.g. urea or guanidine hydrochloride
  • alternative binding and purification conditions e.g. cobalt or nickel affinity columns, anion or cation exchange columns
  • alternative expression conditions e.g. temperature, time, alternative cell lines.
  • PPV5A capsid protein of SEQ ID NO:4 was expressed in a bacterial expression system, generally in accordance with the methods disclosed in EMD Chemicals Inc. Novagen User Protocol TB 184. This method included the addition of an inherent HIS-tag contained in the bacterial vector (EMD Chemicals Inc., 2011 (7)) to facilitate purification of the produced protein. Bacterially expressed HIS-tagged capsid protein was purified generally in accordance with the methods disclosed in GE Healthcare, 2012 (8) and resultant products used to generate PPV5A specific antibodies as described in Example 8.
  • An attenuated subunited vaccine was prepared by combining a purified capsid protein preparation with a carrier preparation.
  • Antibodies that specifically bind to PPV5A are prepared by immunizing rabbits with antigenic preparations of PPV5A virus, or subunit protein preparations of capsid (SEQ ID NO:4) proteins or fragments thereof. Serum samples from the inoculated rabbits are screened for polyclonal antibodies which bind to the PPV5A antigens. Spleens from inoculated mice which were determined to produce antibodies to the antigen are fused with myeloma cells to produce hybridomas. The hybridomas are then screened for binding to PPV5A antigen.
  • Polyclonal antibodies The HIS-tagged bacterially expressed capsid protein prepared in accordance with Example 7 was used to immunize two New Zealand White rabbits at a custom antibody production service (Rockland Antibodies and Assays; Gilbertsville, Pa.).
  • Rabbits were immunized with approximately 100 ⁇ g antigen/rabbit at D0, D7, D14 and D28.
  • D0 and D7 inoculation animals were inoculated intradermally; inoculations given at D14 and 28 were administered subcutaneously.
  • Complete Freund's adjuvant was used in the first inoculation; incomplete Freud's adjuvant was used in subsequent inoculations.
  • Serum samples from both rabbits were collected before immunization and at 38 and 45 days post immunization.
  • Polyclonal antibody preparations were screened for anti-PPV5A specificity by Rockland Antibodies and Assays.
  • Antibodies were produced having binding specificity to purified or partially purified PPV5A protein by immunofluorescent assay (IFA), western blot, and enzyme-linked immunosorbent assay (ELISA). Parameters for specificity of each assay were as follows: western blot specificity were measured by detection of the predicted 88.8 kDa sized protein, IFA specificity measured by comparison to uninfected cells, and ELISA specificity by coating plate with non-relevant protein.
  • IFA immunofluorescent assay
  • ELISA enzyme-linked immunosorbent assay
  • Monoclonal antibodies HIS-tagged baculovirus expressed capsid protein prepared in accordance with Example 7 are used to generate monoclonal antibodies in Balb/c mice at a custom antibody production service (Rockland Antibodies and Assays; Gilbertsville, Pa.). Mice are immunized with various PPV5A antigenic preparations according to standard protocols designed by the custom antibody production facility. The immune response following inoculation is monitored by the custom antibody production facility and antibody candidates are selected for generation of hybridomas. Standard protocols for generation of monoclonal antibodies are well known to those in the art, e.g. as disclosed in Gabriele et al. (9), p. 117-135.
  • Hybridomas are generated by combining B-cell tumor cells cultivated in hybridoma medium to the proliferation phase with spleen cells harvested from inoculated mice determined to produce antibodies to PPV5A antigens according to standard protocols, as disclosed in Gabriele et al. (9), p. 117-135. After fusion and culturing the hybridomas, the hybridomas are screened for binding to PPV5A antigens, and anti-PPV5A producing hybridomas are selected. Monoclonal antibodies produced by hybridomas are purified using affinity chromatography according to standard protocols, as disclosed in Gabriele et al. (9), p. 209-232.
  • High affinity antibodies specific for PPV5A are identified and further characterized, including determining the epitopes to which they bind, the specificity of the antibody with respect to other related virus species, and suitable high affinity antibodies with high specificity for the PPV5A viral antigen(s) are selected, using immunological techniques well known to the art, e.g. ELISA, Westernblot analysis and epitope mapping (Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, N.J.).
  • ELISA Assay Antibodies prepared in accordance with Example 8 are used to measure PPV5A in a biological sample using ELISA procedures. The assay is conducted as follows:
  • Coating antigen selected from the capsid protein of SEQ ID NO:4 is diluted in coating buffer (0.05 M carbonate-bicarbonate buffer; pH 9.6) to achieve a final concentration of 8 ng/ ⁇ l. Plates (High protein binding 96-well ELISA plates Phenix cat no. MPG-655061) are coated with 50 ⁇ l/well of coating antigen. Plates are sealed and incubated for 1 hr. at 37° C. or overnight at 4° C. The coating solution is removed and the plate is wash plate three times with 200 ⁇ l/well PBST (1 ⁇ PBS+0.05%Tween-20).
  • the plate is coated with 300 ⁇ l/well blocking solution (0.5% w/v non-fat dry milk in PBS), sealed and incubated for 1 hr. at 37° C.
  • the blocking solution is removed and the plate is and washed three times with 200 ⁇ l/well PBST.
  • Samples are diluted 1:100 in blocking solution; 100 ⁇ l/well of serum samples are added to the plate. Plates are sealed and incubated for 1 hr. at 37° C. Serum samples are removed and the plate is washed three times with 200 ⁇ l/well PBST.
  • the secondary antibody (HRP-conjugated-goat anti-swine IgG (H+L); Jackson Immuno-Research 114-035-003) is diluted to 1:10,000 in blocking solution and used to coat the plate with 100 ⁇ l/well. Plates are sealed and incubated for 1 hr. at 37° C. The secondary antibody is removed and the plate is washed three times with 200 ⁇ l/well PBST. Plates are coated with 50 ⁇ l/well TMB (3,5,3′,5′-tetramethylbenzidine; KPL cat no. 53-00-01). Plates are incubated at room temperature in the dark for approximately ten minutes. Plates are coated with 50 ⁇ l/well stop solution (2 M H 2 SO 4 ; KPL cat no. 50-85-04). The optical density is read at 450 nm.
  • PCR Assays Gel-based PCR and qPCR assays for PPV5A have been optimized. These assays are conducted as follows: For the qPCR assay, each reaction is prepared by adding the following reagents: 10 ⁇ l/reaction of 2 ⁇ SsoFast probe supermix (BioRad, cat no.
  • reaction is performed on a T100 thermal cycler (Bio-Rad) for one cycle at 95° C. for 2 minutes followed by forty cycles at the following two temperatures: 95° C. for 5 seconds followed by 60° C. for 5 seconds. Data is read using a CFX96 optical imaging system (Bio-Rad).
  • a CFX96 optical imaging system Bio-Rad
  • each reaction is prepared by adding the following reagents: 12.5 ⁇ l/reaction of 2 ⁇ AmpliTaq Gold Mastermix (Applied Biosystems, cat no.
  • composition of matter that comprises at least one PPV5A protein or polypeptide (prototype PPV5A vaccine) in pigs
  • a randomized study using five week old colostrum-deprived-cesarean-derived (CDCD) animals randomized into three groups (see Table 2) is performed. Animals are vaccinated with a composition or a placebo (phosphate buffered saline; PBS) at study day 0 (D0) and D14. Animals are challenged on D28 with material known to contain PPV5A. Clinical observations, rectal temperatures, weight measurements and blood collection are monitored. At D56, animals are necropsied to evaluate macroscopic lesions. The efficacy of the PPV5A vaccine is determined by statistically comparing the percent mortality, viremia (titers and duration), seroconversion (titers and duration) and clinical signs between vaccinated and non-vaccinated animals.
  • compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the following claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US13/796,621 2012-12-17 2013-03-12 Porcine parvovirus 5a, methods of use and vaccine Abandoned US20140170180A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
US13/796,621 US20140170180A1 (en) 2012-12-17 2013-03-12 Porcine parvovirus 5a, methods of use and vaccine
TW107130755A TW201920662A (zh) 2012-12-17 2013-12-16 豬小病毒5a、用法及疫苗
TW102146453A TWI656213B (zh) 2012-12-17 2013-12-16 豬小病毒５ａ、用法及疫苗
AU2014203571A AU2014203571B2 (en) 2012-12-17 2014-01-15 Porcine parvovirus 5A, methods of use and vaccine
KR1020157019338A KR102197266B1 (ko) 2013-03-12 2014-01-15 돼지 파르보바이러스 5ａ, 이용 방법 및 백신
MX2015007723A MX2015007723A (es) 2012-12-17 2014-01-15 PARVOVIRUS PORCINO 5ª, METODOS DE USO Y VACUNA.
EP13814791.3A EP2931741B1 (en) 2012-12-17 2014-01-15 Porcine parvovirus 5a, methods of use and vaccine
UAA201506962A UA117467C2 (uk) 2012-12-17 2014-01-15 Парвовірус свиней 5а, спосіб застосування та вакцина
ES13814791.3T ES2689515T3 (es) 2012-12-17 2014-01-15 Parvovirus porcino 5A, métodos de uso y vacuna
JP2015547995A JP6072935B2 (ja) 2013-03-12 2014-01-15 ブタパルボウイルス５ａ、使用方法およびワクチン
EA201500643A EA031278B1 (ru) 2012-12-17 2014-01-15 Парвовирус свиней 5а, способы применения и вакцина
DK13814791.3T DK2931741T3 (en) 2012-12-17 2014-01-15 Pig Parvovirus 5A, Methods of Use and Vaccine
PCT/US2013/075059 WO2014099669A1 (en) 2012-12-17 2014-01-15 Porcine parvovirus 5a, methods of use and vaccine
CA2894708A CA2894708A1 (en) 2012-12-17 2014-01-15 Porcine parvovirus 5a, methods of use and vaccine
SG11201504805PA SG11201504805PA (en) 2012-12-17 2014-01-15 Porcine parvovirus 5a, methods of use and vaccine
US14/713,700 US9833507B2 (en) 2012-12-17 2015-05-15 Porcine parvovirus 5A, methods of use and vaccine
CL2015001689A CL2015001689A1 (es) 2012-12-17 2015-06-16 Parvovirus 5a porcino, métodos de uso y vacuna
PH12015501378A PH12015501378A1 (en) 2012-12-17 2015-06-17 Porcine parvovirus 5a, methods of use and vaccine
CO15166795A CO7461133A2 (es) 2012-12-17 2015-07-17 Parvovirus 5a porcino, métodos de uso y vacuna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738110P 2012-12-17 2012-12-17
US13/796,621 US20140170180A1 (en) 2012-12-17 2013-03-12 Porcine parvovirus 5a, methods of use and vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/713,700 Division US9833507B2 (en) 2012-12-17 2015-05-15 Porcine parvovirus 5A, methods of use and vaccine

Publications (1)

Publication Number Publication Date
US20140170180A1 true US20140170180A1 (en) 2014-06-19

Family

ID=50931160

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/796,621 Abandoned US20140170180A1 (en) 2012-12-17 2013-03-12 Porcine parvovirus 5a, methods of use and vaccine
US14/713,700 Active 2033-11-22 US9833507B2 (en) 2012-12-17 2015-05-15 Porcine parvovirus 5A, methods of use and vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/713,700 Active 2033-11-22 US9833507B2 (en) 2012-12-17 2015-05-15 Porcine parvovirus 5A, methods of use and vaccine

Country Status (16)

Country Link
US (2) US20140170180A1 (es)
EP (1) EP2931741B1 (es)
AR (1) AR094725A1 (es)
AU (1) AU2014203571B2 (es)
CA (1) CA2894708A1 (es)
CL (1) CL2015001689A1 (es)
CO (1) CO7461133A2 (es)
DK (1) DK2931741T3 (es)
EA (1) EA031278B1 (es)
ES (1) ES2689515T3 (es)
MX (1) MX2015007723A (es)
PH (1) PH12015501378A1 (es)
SG (1) SG11201504805PA (es)
TW (2) TWI656213B (es)
UA (1) UA117467C2 (es)
WO (1) WO2014099669A1 (es)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210097A1 (en) * 2015-06-23 2016-12-29 The Trustees Of Columbia University In The City Of New York Novel equine parvovirus and uses thereof
US9827306B2 (en) 2013-02-15 2017-11-28 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5B, methods of use and vaccine
US9833507B2 (en) 2012-12-17 2017-12-05 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5A, methods of use and vaccine
US10398773B2 (en) * 2014-04-17 2019-09-03 Intervet Inc. Porcine parvovirus
US10485866B2 (en) 2016-11-03 2019-11-26 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus
US10660952B2 (en) 2016-11-03 2020-05-26 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
CN111454969A (zh) * 2019-09-02 2020-07-28 西北农林科技大学 带有双标签猪细小病毒全长感染性克隆制备方法及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102243368B1 (ko) * 2019-04-17 2021-04-23 대한민국 돼지파보바이러스에 특이적인 단일클론항체 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011244A2 (en) * 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Aav4 vector and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
EP0117767A1 (en) 1983-01-07 1984-09-05 Mgi Pharma, Inc. Production of parvovirus subunit vaccines
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
US20030049647A1 (en) * 2001-02-22 2003-03-13 Bassil Dahiyat Use of nucleic acid libraries to create toxicological profiles
WO2011063320A2 (en) 2009-11-23 2011-05-26 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
RU2016144766A (ru) 2014-04-17 2018-05-18 Интервет Интернэшнл Б.В. Парвовирус свиней
BR112017012484B1 (pt) 2014-12-19 2024-02-06 Intervet International B.V Vacina para combater tremor congênito (ct) do grupo a-ii em porcos
US9920302B2 (en) 2015-08-31 2018-03-20 Boehringer Ingelheim Vetmedica Gmbh Pestivirus vaccines for congenital tremors
KR20240090735A (ko) 2016-11-03 2024-06-21 베링거잉겔하임베트메디카게엠베하 돼지 파보바이러스에 대한 백신

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011244A2 (en) * 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Aav4 vector and uses thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Cui et al., "Genome Sequence of Chinese Porcine Parvovirus Strain PPV2010," J. Virol 86(4): 2379 (2012) *
Duffy et al., "Rate of evolutionary change in viruses: patterns and determinants," Nature Reviews Genetics, Vol. 9: 267-276 (2008) *
Lytle et al., "Predicted Inactivation of Viruses of Relevance to Biodefense by Solar Radiation," J. Virol. 79(22): 14244-14252 (2005) *
Lytle et al., "Predicted Inactivation of Viruses of Relevance to Biodefense by Solar Radiation," Journal of Virology, Vol. 70, No. 22: 14244-14252 (2005) *
Ma et al., "The immune enhancement of propolis adjuvant on inactivated porcine parvovirus in guinea pig," Cellular Immunology 270: 13-18 (2011) *
Opreissnig et al., "Effect of porcine parvovirus vaccination on the development of PMWS in segregated early weaned pigs coinfected with type 2 porcine circovirus and porcine parvovirus," Veterinary Microbiology 98: 209-220 (2004) *
SEQID1vXIAOETALJX896318Blast,pdf (2014) *
SEQIDNO2vGorodkinetalBlast.pdf (2014) *
SEQIDNO3621andSEQID3413Blast.pdf (2014) *
Wang et al., "Enhancing immune responses to inactivated porcine parvovirus oil emulsion vaccine by co-inoculating porcine transfer factor in mice," Vaccine 30: 5246-5252 (2012) *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833507B2 (en) 2012-12-17 2017-12-05 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5A, methods of use and vaccine
US9827306B2 (en) 2013-02-15 2017-11-28 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5B, methods of use and vaccine
US10398773B2 (en) * 2014-04-17 2019-09-03 Intervet Inc. Porcine parvovirus
WO2016210097A1 (en) * 2015-06-23 2016-12-29 The Trustees Of Columbia University In The City Of New York Novel equine parvovirus and uses thereof
US10485866B2 (en) 2016-11-03 2019-11-26 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus
US10660952B2 (en) 2016-11-03 2020-05-26 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
US10799578B2 (en) 2016-11-03 2020-10-13 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus
US11730806B2 (en) 2016-11-03 2023-08-22 Boehringer Ingelheim Vetmedica Gmbh Methods of manufacturing an immunogenic composition comprising a recombinant protein
CN111454969A (zh) * 2019-09-02 2020-07-28 西北农林科技大学 带有双标签猪细小病毒全长感染性克隆制备方法及应用

Also Published As

Publication number Publication date
AU2014203571A1 (en) 2015-06-11
CO7461133A2 (es) 2015-11-30
AR094725A1 (es) 2015-08-26
AU2014203571B2 (en) 2017-09-28
TWI656213B (zh) 2019-04-11
EP2931741B1 (en) 2018-07-25
EP2931741A1 (en) 2015-10-21
TW201437369A (zh) 2014-10-01
EA031278B1 (ru) 2018-12-28
DK2931741T3 (en) 2018-10-22
PH12015501378B1 (en) 2015-09-02
SG11201504805PA (en) 2015-07-30
EA201500643A1 (ru) 2015-12-30
ES2689515T3 (es) 2018-11-14
US9833507B2 (en) 2017-12-05
TW201920662A (zh) 2019-06-01
WO2014099669A1 (en) 2014-06-26
CA2894708A1 (en) 2014-06-26
MX2015007723A (es) 2015-09-23
UA117467C2 (uk) 2018-08-10
PH12015501378A1 (en) 2015-09-02
US20150246113A1 (en) 2015-09-03
CL2015001689A1 (es) 2016-09-09

Similar Documents

Publication Publication Date Title
US9833507B2 (en) Porcine parvovirus 5A, methods of use and vaccine
US9827306B2 (en) Porcine parvovirus 5B, methods of use and vaccine
JP2024059815A (ja) ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
AU2018299910B2 (en) Senecavirus a immunogenic compositions and methods thereof
JP5902160B2 (ja) デザイナーペプチドベースのｐｃｖ２ワクチン
US9579373B2 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
US9550812B2 (en) Synthetic capsid proteins and uses thereof
JP6072935B2 (ja) ブタパルボウイルス５ａ、使用方法およびワクチン
CN105263953B (zh) 猪细小病毒5a、使用方法及疫苗
WO2019092027A1 (en) Sapelovirus immunogenic compositions and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOEHRINGER INGELHEIM VETMEDICA, INC., MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IYER, ARUN V.;JORDAN, DIANNA M. MURPHY;PATTERSON, ABBY RAE;AND OTHERS;SIGNING DATES FROM 20130321 TO 20130325;REEL/FRAME:030132/0839

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC., GEORGIA

Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:BOEHRINGER INGELHEIM VETMEDICA, INC.;BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.;REEL/FRAME:053310/0600

Effective date: 20181221